Ionis Pharmaceuticals (IONS) EBITDA (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly EBITDA of -$102.3 million for Q2 2026, down 173.16% year-over-year from $139.8 million in Q2 2025, and up 12.89% quarter-over-quarter from -$117.4 million in Q1 2026.
Ionis Pharmaceuticals (IONS) EBITDA (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at -$102.3 million for Q2 2026.
- In Q2 2026, EBITDA fell 173.16% year-over-year to -$102.3 million; the TTM figure through Jun 2026 stood at -$594.4 million (down 123.01% YoY), while the FY2025 annual figure was -$381.7 million, up 19.66% from the prior year.
- EBITDA for Q2 2026 stood at -$102.3 million, up from -$117.4 million in the prior quarter.
- The five-year high for EBITDA was $139.8 million in Q2 2025, with the low at -$214.5 million in Q4 2025.
- The 5-year median for EBITDA is -$112.5 million (2023), against an average of -$102.2 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA tumbled 1710.21% in 2024, then surged 311.55% in 2025.
- Ionis Pharmaceuticals' EBITDA stood at -$208.0 million in 2022, then soared by 97.06% to -$6.1 million in 2023, then sank by 1710.21% to -$110.8 million in 2024, then sank by 93.52% to -$214.5 million in 2025, then soared by 52.3% to -$102.3 million in 2026.
- Business Quant data shows IONS's EBITDA at -$102.3 million in Q2 2026, -$117.4 million in Q1 2026, and -$214.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | -102.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.29 Mn |
| Mar 31, 2026 | -117.42 Mn |
| Dec 31, 2025 | -214.46 Mn |
| Sep 30, 2025 | -160.18 Mn |
| Jun 30, 2025 | 139.82 Mn |
| Mar 31, 2025 | -146.86 Mn |
| Dec 31, 2024 | -110.82 Mn |
| Sep 30, 2024 | -148.66 Mn |
| Jun 30, 2024 | -66.09 Mn |
| Mar 31, 2024 | -149.51 Mn |
| Dec 31, 2023 | -6.12 Mn |
| Sep 30, 2023 | -143.27 Mn |
| Jun 30, 2023 | -90.20 Mn |
| Mar 31, 2023 | -114.15 Mn |
| Dec 31, 2022 | -208.02 Mn |
| Sep 30, 2022 | -59.15 Mn |
| Jun 30, 2022 | -85.51 Mn |
| Mar 31, 2022 | -57.50 Mn |
| Dec 31, 2021 | 220.60 Mn |
| Sep 30, 2021 | -85.85 Mn |